 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- Changes in US payer biosimilar coverage policies of granulocyte colony-stimulating factor products () - Apr 9, 2024 - Abstract #AMCP2024AMCP_174;
In both cases, average time to policy addition was about 4 months after FDA approval. Further, pegfil- grastim policies had more updates to the preferred product status than filgrastim policies, possibly because of more pegfilgrastim biosimilars being approved and marketed.